A Study in Participants With Type 2 Diabetes Mellitus

NCT01064687 · Completed

Last updated 2026-05-28

This clinical trial is testing a new treatment in adults with type 2 diabetes to see how it affects their blood sugar levels over 26 weeks.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 978 people

Who can join Ages 18+ · all sexes

Timeline Started 2010-02 · est. completion 2012-05

Where 89 sites · Argentina, Mexico, Puerto Rico, United States

What this study is testing ClinicalTrials.gov NCT01064687 ↗

Description as written by the study sponsor.

The purpose of this study is to determine if LY2189265 is effective and safe in reducing hemoglobin A1c (HbA1c), as compared to placebo (no medicine), or exenatide in participants with Type 2 Diabetes. The participants must also be taking metformin and pioglitazone.

Treatments tested

LY2189265 also known as Dulaglutide Drug
Exenatide Drug
Placebo Drug
Metformin Drug
Pioglitazone Drug

Main thing measured	Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01064687 ↗